<DOC>
	<DOCNO>NCT01592474</DOCNO>
	<brief_summary>The purpose study - To examine Avaonex delay development clinically definite multiple sclerosis . - To investigate Avonex delay disability progression slow brain atrophy .</brief_summary>
	<brief_title>Evaluation Brain Atrophy CIS Patients Avonex</brief_title>
	<detailed_description>- Multiple sclerosis ( MS ) chronic inflammatory disorder characterize focal area demyelination central nervous system ( CNS ) . MRI finding suggest look gray matter atrophy marker disease process MS. - Avonex proven effective disease-modifying treatment , reduces total brain GM atrophy consider first-line therapy patient RRMS CIS . - The original SET study open-label observational study high risk subject CIS development CDMS enroll 220 patient start Avonex immediately first clinical attack Czech Republic , follow clinical MRI examination 4 year 0 , 6 , 12 , 24 , 36 48 month . The clinical MRI acquisition examination study conduct Czech Republic .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<criteria>MRI finding must reveal least 2 hyperintense lesion T2WI FLAIR image first clinical onset CSF examination confirm oligoclonal band ( examination must do internationally approve lab CSF take treatment attack start ) Age 18 55 year Effective contraception female patient childbearing potential Kurtzke EDSS â‰¤ 3.5 baseline Willingness accept plan study compliance study Time begin first symptom CIS baseline visit exceed 4 month ( baseline MRI baseline visit organize first 28 day last steroid administration ) CIS attack treat least 3g methylprednisolone without taper In case severe attack 1 g cyclophosphamide disqualify patient study first MRI CSF examination do treatment administer No active major organ disease especially hepatic thyroid origin The clinical diagnosis MS definite ( second attack occur baseline visit ) Age le 18 55 Noneffective contraception method pregnancy plan Active major organ disease , especially hepatic endocrinologic Cooperation subject ensure Kurtzke EDSS high 3.5 baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Avonex</keyword>
	<keyword>Brain atrophy</keyword>
	<keyword>MRI</keyword>
	<keyword>Interferon-beta 1a</keyword>
	<keyword>IFN Beta 1-a</keyword>
	<keyword>Clinically isolated syndrome</keyword>
	<keyword>CIS</keyword>
</DOC>